|
목적 : To investigate the clinical implications of cysteine rich angiogenic inducer 61 (CYR61) in Graves’ orbitopathy (GO) by evaluation of serum CYR61 concentrations and CYR61 mRNA expression in patients with GO.
방법 : Sera from 40 GO patients and 20 healthy controls, and orbital fat tissue samples from 15 GO patients and eight control subjects were included for analysis. Concentrations of CYR61 were measured from sera, and CYR61 mRNA expression levels were evaluated from orbital fat tissue, and compared between GO patients and control subjects.
결과 : Serum CYR61 levels were higher in GO patients than in controls (p = 0.001), especially for patients in the active inflammatory phase (p = 0.031). The cutoff value of serum CYR61 for distinguishing active GO was 117.0 pg/dL with sensitivity of 72.2% and specificity of 73.8%. Thyrotropin-binding inhibitor immunoglobulin showed a positive correlation with serum CYR61 levels (r = 0.434, p = 0.005). Expression of CYR61 mRNA was 9.2-fold higher in patients with GO than that of normal controls (p = 0.001).
결론 : The increased mRNA expression of CYR61 in GO patients and elevated serum CYR61 levels in patients with active GO suggest that CYR61 could be an adjuvant biomarker associated with the inflammatory activity of GO.
|